Apellis Pharmaceuticals, Inc.

Ownership Transactions Reported by 22 Insiders

Symbol
APLS on Nasdaq
Location
100 Fifth Avenue, Waltham, MA

Insiders trading volume in the past year

Apellis Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Morningside Venture Investments Ltd 10%+ Owner $816M Nov 18, 2021
Cedric Francois Chief Executive Officer, Director $69.4M -$16.9M -19.6% Jan 29, 2025
Pascal Deschatelets Chief Scientific Officer $34.7M -$11.6M -25.1% Jan 29, 2025
Timothy Sullivan Chief Financial Officer $11.5M -$838K -6.79% Jan 29, 2025
Alec Machiels Director $11.3M Jan 1, 2025
Lukas Scheibler Chief Research Officer $6.96M Dec 1, 2023
David Watson General Counsel $6.63M -$501K -7.03% Jan 29, 2025
Federico Grossi Chief Medical Officer $6.04M Jan 5, 2023
Sinclair Dunlop Director $3.58M -$3.86M -51.9% Jan 1, 2025
Mark DeLong Chief Business & Strat Officer $3.47M -$700K -16.8% Jan 29, 2025
Caroline Baumal Chief Medical Officer $2.8M -$151K -5.12% Jan 17, 2025
Adam Townsend Chief Commercial Officer $2.48M -$265K -9.64% Jan 29, 2025
Nur Nicholson Chief Technical Officer $2.47M -$930K -27.4% Jan 29, 2025
Karen Lewis Chief People Officer $2.07M -$147K -6.62% Jan 29, 2025
Jeffrey Eisele Chief Development Officer $1.63M -$57.1K -3.38% Jan 29, 2025
Victoria Brown Program Team Lead $1.5M Jan 20, 2023
James Chopas VP/Chief Accounting Officer $1.46M -$116K -7.36% Jan 22, 2025
Keli Walbert Director $815K Jan 8, 2025
Nicole Perry Vice President - Accounting $717K Aug 2, 2021
R. Paul Fonteyne Director $696K Jan 1, 2025
Gerald Chan Director $626K Jan 1, 2025
Stephanie O'Brien Director $626K Jan 1, 2025

Recent Insider Transactions by Companies or Individuals for Apellis Pharmaceuticals, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.